Dr. Zibelman on Determining Treatments for Patients with RCC | OncLive

Dr. Zibelman on Determining Treatments for Patients with RCC

October 3, 2017

Matthew R. Zibelman, MD, assistant professor, Department of Hematology/Oncology, Fox Chase Cancer Center, discusses determining treatments for patients with renal cell carcinoma (RCC).

Matthew R. Zibelman, MD, assistant professor, Department of Hematology/Oncology, Fox Chase Cancer Center, discusses determining treatments for patients with renal cell carcinoma (RCC).

After standard therapy with tyrosine kinase inhibitors (TKIs), there is currently no good data to guide what regimen should come next, states Zibelman. Nivolumab (Opdivo) has been well tolerated, which has made it appealing to many patients. Additionally, patients with bone metastases tend to respond well to cabozantinib (Cabometyx).


x